Anti-TJP1 antibody produced in rabbit

Description

• General description: Tight junction protein 1/Zona occludens 1 protein (TJP1, ZO-1) is a membrane-associated guanylate kinase, associated with cytoplasmic membrane surface of intercellular tight junctions. ZO-1 gene is mapped to human chromosome 15q13.1. It comprises a guanylate kinase (GUK) domain, three postsynaptic density 95/disc-large/ZO-1 (PDZ) domains, a Src homology 3 domain, actin-binding region and an acidic domain. ZO-1 is observed in the tight junctions associated with epithelia and endothelia.
• Specificity: Rabbit polyclonal anti-TJP1 antibody reacts with human tight junction protein 1/zona occludens 1 protein.
• Immunogen: Tight junction protein ZO-1 recombinant protein epitope signature tag (PrEST)
• Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
• Biochem/physiol Actions: Tight junction protein 1/Zona occludens 1 protein (TJP1/ZO-1) mediates the regulation of cell remodeling and tissue organization in both the embryonic and extraembryonic regions. It binds with other proteins including junctional adhesion molecule (JAM), claudins and occludin. ZO-1 deficiency also favors apoptosis in the embryonic cells. Silencing of the ZO-1 by the microRNA (miR-103) increases endometrial carcinogenesis and could be a potential therapeutic target. The levels of ZO-1 are elevated in hepatocellular carcinoma.
• Features and Benefits: Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways:IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.Protein array of 364 human recombinant protein fragments.
• Linkage: Corresponding Antigen APREST83050
• Physical form: Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
• Legal Information: Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.